These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28912139)

  • 1. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
    Gu L; Deng ZJ; Roy S; Hammond PT
    Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
    [No Abstract]   [Full Text] [Related]  

  • 2. Small RNA combination therapy for lung cancer.
    Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
    Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of
    Zhao G; Ho W; Chu J; Xiong X; Hu B; Boakye-Yiadom KO; Xu X; Zhang XQ
    ACS Appl Mater Interfaces; 2023 Jul; 15(26):31273-31284. PubMed ID: 37354089
    [No Abstract]   [Full Text] [Related]  

  • 7. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
    Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
    Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
    Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
    Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrilase 1 modulates lung tumor progression in vitro and in vivo.
    Wang YA; Sun Y; Le Blanc JM; Solomides C; Zhan T; Lu B
    Oncotarget; 2016 Apr; 7(16):21381-92. PubMed ID: 26967383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.
    Talekar M; Trivedi M; Shah P; Ouyang Q; Oka A; Gandham S; Amiji MM
    Mol Ther; 2016 Apr; 24(4):759-69. PubMed ID: 26686386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
    Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
    Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells.
    Wang M; Chen X; Fu G; Ge M
    Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36222298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting
    Uras IZ; Moll HP; Casanova E
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
    Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
    Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.